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Integrated analysis of global 
proteome, phosphoproteome, 
and glycoproteome enables 
complementary interpretation of 
disease-related protein networks
Jong-Moon Park1,*, Ji-Hwan Park2,*, Dong-Gi Mun3,*, Jingi Bae3,*, Jae Hun Jung4, 
Seunghoon Back3, Hangyeore Lee3, Hokeun Kim3, Hee-Jung Jung6, Hark Kyun Kim5, 
Hookeun Lee1, Kwang Pyo Kim4, Daehee Hwang2,6 & Sang-Won Lee3
Multi-dimensional proteomic analyses provide different layers of protein information, including 
protein abundance and post-translational modifications. Here, we report an integrated analysis of 
protein expression, phosphorylation, and N-glycosylation by serial enrichments of phosphorylation 
and N-glycosylation (SEPG) from the same tissue samples. On average, the SEPG identified 142,106 
unmodified peptides of 8,625 protein groups, 18,846 phosphopeptides (15,647 phosphosites), 
and 4,019 N-glycopeptides (2,634 N-glycosites) in tumor and adjacent normal tissues from three 
gastric cancer patients. The combined analysis of these data showed that the integrated analysis 
additively improved the coverages of gastric cancer-related protein networks; phosphoproteome 
and N-glycoproteome captured predominantly low abundant signal proteins, and membranous or 
secreted proteins, respectively, while global proteome provided abundances for general population of 
the proteome. Therefore, our results demonstrate that the SEPG can serve as an effective approach for 
multi-dimensional proteome analyses, and the holistic profiles of protein expression and PTMs enabled 
improved interpretation of disease-related networks by providing complementary information.
Multiple types of information, including protein abundances and various post-translational modifications (PTMs), 
such as phosphorylation or glycosylation, are required to understand activities of multilayered cellular protein 
networks. Comparison of protein abundances between two conditions reveals alterations in activities of cellular 
protein networks that can be reflected by protein abundances. Also, phosphorylation levels represent activities of 
signaling pathways in cellular protein networks. The levels of other PTMs, such as ubiquitination or acetylation, 
represent the states of the proteins, thereby reflecting activities of cellular protein networks associated with such 
states of the proteins. Thus, multi-dimensional proteomic analyses have been employed to acquire multiple types 
of protein data to decode diverse activities of cellular protein networks.
Mass spectrometry (MS)-based global proteome analysis has provided abundance data only for a limited 
number of proteins, compared to transcriptomic analysis, to understand activities of cellular protein networks. 
Moreover, due to relatively low abundances of PTMs, the enrichment of peptides with PTMs is commonly employed 
prior to liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis, which requires larger amounts 
of samples for profiling the peptides with PTMs, compared to transcriptomic analysis. However, recent advances in 
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extensive fractionation, high-resolution peptide separation, and high performance mass spectrometry significantly 
improved the proteome size as to be comparable to the transcriptome size detected by mRNA-sequencing. For 
example, Branca et al. measured the abundances of 13,078 proteins from human A431 cells using high-resolution 
isoelectric focusing prefractionation1. Moreover, serial enrichment methods of peptides with PTMs from the 
same sample have been developed to significantly reduce the sample amount required. For example, Mertins et al. 
developed serial enrichments of different post-translational modifications (SEPTM) for an integrated analysis of 
protein abundance, phosphorylation, ubiquitination, and acetylation from the same sample2. The SEPTM method 
enabled quantitative analysis of about 8,000 proteins, and 20,000 phosphorylation, 15,000 ubiquitination and 3,000 
acetylation sites per experiment in human leukemia cells, permitting a holistic view of cellular signal pathways.
Such advances in MS-based proteomic analysis have facilitated multi-dimensional proteomic analyses for 
understanding activities of multilayered protein networks. Swaney et al. performed an integrated analysis of phos-
phoproteome and ubiquitinated proteomes in Saccharomyces cerevisiae and identified 466 proteins with 2,100 
phosphorylation sites co-occurring with 2,189 ubiquitinated sites3. Using these data, they found interplays between 
the signaling networks represented by phosphorylation and ubiquitination and identified phosphorylation sites 
regulating ubiquitin-dependent protein degradation based on the interplays. Likewise, many of these studies 
focused on cellular protein networks commonly represented by different types of proteomic data. For example, the 
integrated analysis of phosphoproteome and lysine-acetylome in Mycoplasma pneumonia revealed interplays of the 
protein networks represented by the two PTMs4. These studies have showed that multiple types of proteome pro-
files can add both depth of detection and complementary information. However, how different types of proteomic 
data complementarily improved interpretation of cellular protein networks has not been systematically examined.
Here, we present a MS-based method for multi-dimensional proteomic analyses of protein abundance, phospho-
rylation, and N-glycosylation by serial enrichments of phosphorylation and N-glycosylation from the same tissue 
samples. In this method, isobaric tag for relative and absolute quantitation (iTRAQ) labeled peptides from human 
gastric cancer and adjacent normal tissues of a patient were subjected to fractionation by mid-pH reverse phase 
LC (RPLC) and then to the immobilized-metal affinity chromatography (IMAC) method for the phosphopeptide 
enrichment, followed by a filter aided capture and elution (FACE) for the N-glycopeptide enrichment. Our serial 
enrichment method is a variation of the SEPTM method developed by Mertins et al.2 to add the enrichment of 
N-glycosylated peptides without the enrichment of ubiquitinated and acetylated peptides. LC-MS/MS analysis 
provided global proteome, phosphoproteome, and N-glycoproteome for the cancer and normal tissues from three 
patients. The combined analysis of these data demonstrated that different types of data provided complementary 
coverages of gastric cancer-related protein networks, thereby facilitating improved interpretation of the networks.
Methods
Tissue collection. Gastric tissues samples (cancer and adjacent normal tissues) were collected from three 
patients with gastric cancer who underwent gastrectomies at Asan Medical Center and Chonnam University 
Hwasun Hospital, which are members of National Biobank of Korea (2013-7 and 07SA2013010-001) 
(Supplementary Table S1). The methods for tissue processing were approved in accordance with the experimental 
protocols by the National Biobank of Korea. Institutional review board (AMC-2012-0576, NCCNCS-120581)-
approved informed consents were signed by all subjects. There were 2 males (66.7%) and median age was 44 years 
(40–45). All three tumors were diffuse type in histology and microsatellite-stable. At the time of diagnosis, two 
patients were stage IIB and one patient was at stage IV. No patients received prior chemotherapy or radiotherapy. 
After gross examination, non-necrotic portions were excised from resected tumor specimens by pathologists and 
immersed in liquid nitrogen within 30 minutes after resection. Tissue lysis was performed for tumor-rich area of 
each cancer tissue that was identified by the light microscopic evaluation of hematoxylin and eosin-stained top 
slides. Adjacent normal tissues were taken from the luminal side of the gastrectomy specimen, at least 2cm apart 
from the tumor border, and immersed in liquid nitrogen at the same time with the tumor tissues of the same 
patients.
Serial enrichments of phosphorylation and N-glycosylation (SEPG) from the same tissue 
sample. We developed an integrated method for profiling global proteome, phosphoproteome, and 
N-glycoproteome by SEPG from the same tissue samples (Fig. 1). In this method, we used a FASP for protein 
digestion. The method permits to use sodium dodecyl sulfate, a potent detergent for solubilizing hydrophobic 
membranous proteins, and thereby to produce ‘universal’ proteome from nucleus to membrane and extracellular 
matrix5, which can facilitate the integrated multi-dimensional proteomic analyses. The peptides obtained from 
the pair of tumor and adjacent normal tissues of a gastric cancer patient were then individually double-labeled 
with 4-plex iTRAQ reagents (Supplementary Methods).
We next used a mid-pH RPLC fractionation (mRP fractionation) from which the initial 96 fractions of the 
iTRAQ-labeled peptides were noncontiguously pooled into 24 fractions (Fig. 1; Supplementary Methods). In the 
mRP fractionation, we used triethylammonium bicarbonate (TEAB) solvents (pH 7.5), instead of the conventional 
ammonium formate solvents (pH 10)6. TEAB was chosen for three reasons: better compatibility with iTRAQ 
labeling, high volatility, and less detrimental effects on the separation column. As iTRAQ labeling uses TEAB as 
a buffer, we concentrated the iTRAQ-labeled peptide solution down to a small volume (i.e. 200 μ L), rather than 
completely drying, and directly injected for the subsequent mRP fractionation. Also, due to the high volatility of 
TEAB, mRP fractions were dried and directly used in the subsequent LC-MS/MS or IMAC experiments. Finally, 
the use of TEAB for the mRP fractionation showed no degradation to the C18 column over a period of 1 year usage 
and up to more than 100 fractionation experiments, whereas the ammonium formate in the buffers was reported 
to have detrimental effects on column7.
Next, individual mRP fractions (10 μ g, ca. 7%) were subjected to LC-MS/MS experiments to profile global 
proteome. The rest peptides were concatenated into 12 fractions (Supplementary Methods) each of which was 
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then subjected to the phosphopeptide enrichment experiments, and the flow-throughs in the IMAC experiments 
were used for the N-glycopeptide enrichment experiments8,9 (Fig. 1). The entire procedure of the SEPG developed 
for the integrated multi-dimensional proteome analyses was performed without a single offline desalting step.
The combined use of two orthogonal dimensions (i.e. mid-pH RP and low-pH RP)10 and the noncontiguous 
pooling strategy effectively spread the complex peptide mixture into peptide fractions of even complexity as evi-
denced by uniform distributions of identified peptides over the RPLC retention time across the 24 fraction LC-MS/
MS experiments (Supplementary Fig. S1). The effective fractionation was also supported by the observations of 
ca. 80% and 88% of the global and phosphopeptides, respectively, being uniquely identified from the individual 
fractions on average (Supplementary Fig. S2). Relatively small portion (ca. 54%) of N-glycopeptides being uniquely 
identified from the individual fraction (Supplementary Fig. S2) may reflect the inherent complex nature of protein 
glycosylation, as a single glycosylation site was previously observed to be occupied by many structurally different 
glycans11. These N-glycosylated peptides of different glycans will be fractionated into different fractions, but will 
become the same deglycosylated peptides (with Asn → Asp) after deglycosylation by PNGase F during FACE 
enrichment experiments, resulting in the same deglycosylated peptides in different fractions.
Identification of differentially expressed proteins, phosphoproteins and glycoproteins. The 
raw data used in this study were deposited into PRIDE database (dataset identifier PXD003115)12,13. iTRAQ inten-
sities of the 143,020, 140,165, and 143,133 aligned peptides (on average, 142,106 peptides; Supplementary Table 
S2a–c) were normalized using the quantile normalization method14. Log2-fold-changes of the proteins between 
gastric cancer and adjacent normal tissues were estimated using the linear-programming method, as previously 
described15, based on the bipartite graph representing protein groups. Of these quantified proteins, the proteins 
more than two non-redundant peptides were chosen for the following analyses. First, a statistical hypothesis test 
for the log2-fold-changes was used to identify differentially expressed proteins (DEPs)16. An empirical null distri-
bution was estimated by applying Gaussian kernel density estimation method to log2-fold-changes obtained after 
performing all possible permutations of 114–117 labels17. The proteins with P < 0.05 at least in one of the three 
tissue pairs were identified as the DEPs. Second, for 19,421, 16,973, and 20,144 phosphopeptides and 4,405, 4,161, 
and 3,491 N-glycopeptides (on average, 18,846 phosphopeptides and 4,019 N-glycopeptides; Supplementary 
Figure 1. Overall workflow in the SEPG method for integrated profiling of global proteome, 
phosphoproteome, and N-glycoproteome. First, iTRAQ-labeled peptides were fractionated into 24 fractions 
using mRP fractionation on the 96-well plate as schematically described (top left). For each of 24 fractions, 
global profiling was then performed, and the remaining 24 fractions were further concatenated into 12 
fractions. For each of the 12 fractions, IMAC enrichment was performed, followed by phosphoproteome 
profiling. Finally, for the flow-throughs of the 12 fractions from the IMAC experiments, N-glycopeptide 
enrichment was performed, followed by N-glycoproteome profiling.
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Table S2a–c), the quantile normalization and the same statistical method was used at the peptide level. The empir-
ical distribution and P-values were estimated for the log2-fold-changes of the peptides. Differentially phospho-
rylated proteins (DPPs) and differentially N-glycosylated proteins (DGPs) were identified as the proteins that 
contained the unique phosphopeptides and N-glycopeptides with P < 0.05, or the unique peptides detected exclu-
sively in either the gastric tissue or the normal tissue. Finally, the enrichment analyses of gene ontology biological 
processes (GOBPs), gene ontology cellular components (GOCCs), and Kyoto encyclopedia of genes and genomes 
(KEGG) pathways18 were performed for the DEPs, DPPs, and DGPs using ConsensusPathDB19 software. The 
GOBPs, GOCCs, and KEGG pathways represented by the DEPs, DPPs, and DGPs were identified as the ones with 
P < 0.1 (a default cutoff). Alternatively, Z score was also computed as Z = N−1 (1 − P), where N−1(∙) is the inverse 
standard normal distribution and P is the enrichment P-value.
Five types of cellular protein networks. We categorized the cellular protein networks in the KEGG path-
way database to the following five groups as shown in Supplementary Table S3: 1) metabolic networks, 2) cellular 
signaling networks, 3) cell cycle, DNA, and RNA processing networks, 4) protein homeostasis networks, and 5) 
cellular and organic interaction networks. The proteins in the cellular signaling networks were further grouped 
into receptor ligands, receptors, kinases/phosphatases, and transcription factors based on the gene ontology 
molecular functions (‘Receptor binding’, ‘Receptor activity’, ‘Kinase activity’, ‘Phosphatase activity’, and ‘Nucleic 
acid binding transcription factor activity’, respectively).
Construction of cellular network models for complementary coverages. The 191,822 protein- 
protein interactions (PPIs) for the 16,382 proteins were obtained from the Biological General Repository for 
Interaction Datasets (BioGRID)20, CCSB interactome database (CCSB)21–24, the Human Protein Reference 
Database (HPRD)25, the IntAct molecular interaction database (IntAct)26, the Molecular INTeraction database 
(MINT)27, and the Database of Interacting Proteins (DIP)28, as shown in Supplementary Table S4. The networks 
for the CC1-3 were constructed by adding the PPIs to the DEPs, DPPs, and DGPs to the interactions in the cor-
responding KEGG pathways.
Identification of hub-like molecules and nodes with large clustering coefficient. Using the PPIs 
described above, we computed the number of interactors (degree) and clustering coefficient for each protein 
in the following sets: 1) DEPs, 2) DEP + DPPs, 3) DEP + DGPs, and 4) DEP + DPP + DGPs. For each set, the 
empirical distribution of the degree was estimated by randomly sampling the same number of proteins from the 
whole proteome with PPIs 1,000 times and then by computing the degrees for the randomly sampled proteins. 
Based on the empirical distribution, the P-value for each protein was computed using the right-sided test, and 
the proteins with P < 0.05 were identified as the hub-like molecules. The same procedure was used to compute 
P-values for clustering coefficients and to select the nodes with large clustering coefficients (P < 0.05).
TF and kinase enrichment analysis. To identify key TFs regulating the DEPs, 304,217 protein-DNA inter-
actions (PDIs) were first collected from the human transcriptional regulation interactions database (HTRIdb)29, 
transcriptional regulatory element database (TRED)30, Amadeus31, the molecular signatures DB (MSigDB)32, 
EdgeExpress database (EEDB)33, a database of regulatory information for human bZIP transcription factors 
(bZIPDB)34, and MetaCore™ (GeneGo, St. Joseph, MI, USA) shown in Supplementary Table S5. For each TF, 
the number of targets in the DEPs was calculated using the PDI data, and P-value for the number of targets was 
then computed based on the hypergeometric distribution by applying Fisher’s exact test. Of the TFs with P < 0.05, 
the TFs belonging to the DEPs or DPPs were chosen as the key regulators. To identify key kinases regulating the 
DPPs, 5,563 kinase-substrate interaction data were also collected from PhosphoSitePlus® 35, Phospho.ELM36, and 
PhosphoPOINT37 (Supplementary Table S6). The same method was applied to the kinase-substrate interaction 
data and the DPPs. Of the kinases with P < 0.05, the kinases belonging to the DEPs or DPPs were selected as 
key kinases. For the following two groups, we calculated the network density (D) as E/nC2, where E and n is the 
number of interactions and nodes in the network, respectively, and nC2 is the number of possible interactions in 
the network: 1) 17 key TFs and kinases belonging to the DEPs, and 2) 30 key TFs and kinases belonging to the 
DEPs or DPPs. For the network density of each group, we estimated an empirical distribution of D by randomly 
sampling the same number of proteins with the group from the 1,320 TFs and kinases with PPIs 100,000 times 
and then computed P-values of the observed D based on the empirical distribution using the right-sided test.
Results
Multi-dimensional proteomes obtained by the SEPG method. To understand the characteristics 
of the multi-dimensional proteomes measured by the SEPG method, we first identified the peptides from the 
three proteomes using the Uniprot protein sequences (May, 2013; 90,191 entries) in the target-decoy setting 
by the MS-GF+ (v9387) search engine38 (Methods). For 24 global LC-MS/MS datasets, on average, we identi-
fied 142,106 non-redundant peptides (8,625 protein groups) for the three patients (Supplementary Table S2a-c, 
S7a-c and Fig. 2a). We also identified 18,846 phosphopeptides (15,647 phosphosites) and 4,019 N-glycopeptides 
(2,634 N-glycosites), on average (Supplementary Table S2a-c, S7a-c and Fig. 2a), belonging to 4,560 and 1,140 
protein groups, respectively. Importantly, the three proteomes increased cumulatively the coverage of the cellular 
proteome (Fig. 2b). Global proteomes detected from the three patients were mapped to 9,361protein coding 
genes (on average, 7,884 protein coding genes per patient), and phosphoproteomes were mapped to 5,648 genes, 
1,376 of which were additionally identified by phosphoproteome analysis. Furthermore, N-glycoproteomes were 
mapped to 1,343 genes, 277 of which were identified uniquely by N-glycoproteome analysis.
This incremental protein identification by the three proteomes suggests complementary coverages of cellular 
proteome networks. Some PTMs can occur predominantly in particular cellular organelles, thereby their proteomes 
representing mainly the networks associated with the organelles39,40. To understand the complementary nature 
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of the three proteomes in representing cellular protein networks, we first compared what proportions of the three 
proteomes included the proteomes of the five major organelles, nucleus, plasma membrane, endoplasmic reticulum 
(ER)/Golgi apparatus, extracellular region, and cytosol, based on gene ontology cellular components of the proteins 
identified from the three proteomes (Fig. 2c). Of the three proteomes, the N-glycoproteome most significantly 
represented the proteins that were localized in plasma membrane (31.0%) or ER/Golgi secretory pathways (22.1%), 
and secreted to extracellular region (30.2%), consistent to the previous findings41.
We then examined the proportions of the three proteomes to represent the proteins in the five types of cellular 
protein networks in KEGG pathway database18: 1) metabolic networks, 2) cellular signaling networks, 3) cell cycle, 
DNA, and RNA processing networks, 4) protein homeostasis networks, and 5) cellular and organic interaction 
networks (Supplementary Fig. S3 and Fig. 2d). Of these networks, interestingly, the cellular signaling networks 
were significantly represented by all the three proteomes (Fig. 2d). Specifically, the N-glycoproteome significantly 
represented the receptors and their ligands, and the phosphoproteome represented the kinases/phosphatases and 
the downstream transcription factors (TFs) in the signaling networks (Fig. 2e). In contrast, the global proteome 
included uniformly all the above groups of the signaling molecules. These data suggest that the three proteomes 
obtained by the SEPG method provide complementary coverages of cellular protein networks.
Cellular protein networks altered in gastric cancers. To understand the proteomes altered in gastric 
cancers, we first quantified protein abundance changes (log2-fold-changes) between tumor and adjacent normal 
tissues using the iTRAQ data obtained from the global proteome as previously described (Methods). From the 
three tissue pairs, we identified a total of 2,779 differentially expressed proteins (DEPs) between tumor and adja-
cent normal tissues with P < 0.05 (Supplementary Table S8a and Fig. 3a; Methods). From the phosphoproteome 
and N-glycoproteome data, we further identified 1,783 differentially phosphorylated peptides [782 differentially 
phosphorylated proteins (DPPs)], and 521 differentially N-glycosylated peptides [182 differentially glycosylated 
proteins (DGPs)] with P < 0.05 (Supplementary Table S8b, c and Fig. 3a; Methods). In total, 3,346 proteins were 
altered in abundances, phosphorylation, or N-glycosylation (Fig. 3a).
Figure 2. Multi-dimensional proteomes measured by the SEPG method. (a) Averaged numbers of 
identified peptides from global proteomes, phosphoproteomes, and N-glycoproteomes for the three gastric 
cancer patients. Data were shown as means ± SD. (b) Numbers of protein coding genes measured by the three 
proteomes. Colored stacked bar graphs showed incremental identifications of the genes by the indicated multi-
dimensional proteomes (see color legend). (c–e) Percentages of proteins measured by the three proteomes 
that were localized in the indicated five major organelles based on their gene ontology cellular components 
(c) and that were involved in the cellular signaling networks in the KEGG pathway database (d,e) Percentages 
of proteins involved in the cellular signaling networks that belonged to the indicated four groups of signaling 
molecules.
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The complementary nature of global proteome (DEPs), phosphoproteome (DPPs), and N-glycoproteome 
(DGPs) can provide the increase in both ‘depth of detection’ and ‘diversity of information’ afforded by the 
multi-dimensional proteome analyses. To explore the complementary characteristics of the 3,346 proteins in 
representing cellular networks, we categorized them into seven groups (Groups 1–7) based on their alteration 
patterns in abundances, phosphorylation, and N-glycosylation (Fig. 3b). Of them, Groups 1–3 showed altera-
tions uniquely in each type of the data. The non-overlapping nature of Groups 1–3 across individual data types 
provides the increased coverage of the cellular protein networks through the increased depth of detection. To 
Figure 3. Complementary nature of the three proteomes altered in gastric cancers. (a) Relationships among 
the sets of the altered proteins in gastric cancers (DEPs, DPPs, and DGPs). (b) Seven groups of the altered proteins 
(G1-7) that were further categorized into two classes representing the altered proteins in single types of the three 
proteomes (G1-3) and more than one type of the three proteomes (G4-7), respectively. (c–f) Cellular protein 
networks in KEGG pathway database associated with Complementary Coverages 1–4 (see text for definition). 
The color in the heat maps represents the significance measures, Z scores defined as –N−1(P) where N−1 is the 
inverse Gaussian function and P is the enrichment P-values obtained from ConsensusPathDB software. Color bar, 
gradients of the Z scores. The group to which each cellular protein network belonged was also indicated next to the 
heat maps (see legend for the network groups).
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examine this, we identified KEGG pathways represented distinctively by Groups 1–3 (Fig. 3c; Complementary 
Coverage 1). Group 1 (DEPs) uniquely represented alterations in metabolic networks (glycolysis/gluconeogenesis, 
pentose phosphate pathway, and glycerolipid/steroid/retinol metabolism). Group 2 (DPPs) uniquely represented 
alterations in signaling networks (chemokine, calcium, insulin, Erbb, and mTOR signaling pathways). Moreover, 
Group 3 (DGPs) represented uniquely alterations in cellular and organic interaction networks (cytokine-receptor 
interaction). These data showed that the complementary coverage 1 (CC1) provided the increased coverage of the 
altered protein networks in gastric cancers, including metabolic (Group1), signaling (Group 2), and cellular and 
organic interaction networks (Group 3), by the increased depth of detection.
Alternatively, despite their non-overlapping nature, Groups 1–3 also represented the same protein networks, 
but different parts of such networks (Fig. 3d; Complementary Coverage 2). Unlike the CC1, the complementary 
coverage 2 (CC2), which was defined by two of Groups 1–3, provided the increased coverage of cellular protein 
networks by the increased diversity of information afforded by the multi-dimensional proteome analyses. For 
example, leukocyte transendothelial migration, a cellular and organic interaction network, was represented by 
Groups 1 (DEPs) and 2 (DPPs), indicating that the DPPs additionally represented signaling pathways in the net-
work. Similarly, two of the three proteomes collectively represented alterations in cellular and organic interaction 
networks (focal adhesion, tight junction, and ECM-receptor interaction), and signaling networks (PI3K-AKT 
signaling pathway).
Moreover, Groups 4–7 showed alterations in more than two types of data. Different types of altered information 
for the same proteins (e.g., differential expression and phosphorylation for Group 4) can provide complementary 
states of the proteins in representing activities of the cellular protein networks (Fig. 3e; Complementary Coverage 3). 
The complementary coverage 3 (CC3) provided the increased coverage of cellular protein networks by the increased 
diversity of information due to the multiple types of the information in Groups 4–7. To examine this, the pathway 
enrichment analysis was performed for Groups 4–7. Group 4 represented alterations in signaling networks (mTOR, 
insulin, cGMP-PKG, and calcium signaling) in terms of protein abundances (DEPs) and signaling activities (DPPs) 
at the same time. Also, Group 5 represented alterations in metabolic networks (drug and retinol metabolism), 
signaling networks (PI3K-Akt signaling), and cellular and organic interaction networks (antigen processing and 
presentation) in terms of protein abundances (DEPs) and secretability (DGPs) at the same time. These data showed 
that the CC3 provided the increased coverage of the signaling and metabolic networks represented by Groups 
4–5 by the multiple types of information in Groups 4–5 (increased diversity of information). Finally, similar to 
the CC2, more than two of Groups 4–7 also represented the same protein networks, but different parts of such 
networks (Fig. 3f; Complementary Coverage 4). Due to the nature of Groups 4–7 showing alterations in more 
than two types of data, the CC4 provided the increased coverage of the altered protein networks by the increased 
diversity of information, similar to the CC3.
Complementary coverages of protein networks altered in gastric cancers. To understand com-
plementary coverages of cellular networks altered in gastric cancers at the molecular level, we next constructed 
the network models delineating the Complementary Coverages 1–4 (CC1-4) using molecular interactions in the 
KEGG pathway database. Groups 1–3 associated with CC1 and CC2 included larger numbers of the proteins 
(DEPs, DPPs, and DGPs) altered in gastric cancers, compared to Groups 4–7 associated with CC3 and CC4 
(Fig. 3b). Moreover, Groups 4–7 represented only few networks associated with CC4, compared to those with 
CC3 (Fig. 3e,f). Thus, in this network modeling, we focused on the networks associated with CC1-3.
First, the networks for CC1 were uniquely defined by single types of the proteomes altered in gastric cancers 
(Fig. 4a). PPAR signaling network (Fig. 4a, left) showed alterations of fatty acid uptake (SLC27A2/6) and trans-
ports (FABP1-6) in gastric cancers, leading to dysregulated activation of PPAR pathways, resulting in alteration 
of PPAR targets involved in lipid homeostasis. These alterations were defined mainly by the DEPs. In contrast, 
alterations of ErbB signaling network (Fig. 4a, right) were mainly defined by the DPPs including protein kinase 
C (PRKCA/B) and mitogen activated protein kinase (ARAF, MAP2K2, and MAPK1), and mTOR (MTOR and 
EIF4EBP1) signaling molecules, as well as their downstream TFs (ELK1 and JUN).
Second, the networks for CC2 were collectively defined by two types of the proteomes. PI3K-AKT signaling 
network (Fig. 4b) showed alterations of upstream regulators (collagens, laminins, and integrins) and signaling 
molecules (PTEN, RAC, MAPK, and MTOR) and downstream TFs (FOXO3 and RBL2). Many of these molecules 
belonged to the DGPs and DPPs, indicating that both phosphoproteome and N-glycoproteome collectively defined 
the altered activity of PI3K-AKT network in gastric cancers. Interestingly, the DEPs also provided additional 
information for the altered network in terms of protein abundances, although the enrichment P-value was not 
significant due to the large number of the DEPs in Group 1.
Third, the networks for CC3 were commonly defined by two types of the proteomes. Phosphatidylinositol 
signaling system network (Fig. 4c) included inositol trisphosphate receptors and kinases (ITPR2, ITPR3, and 
ITPKA) and their downstream signaling molecules (CAML5, PRKCA, and PRKCB), which belonged to the DEPs 
and DPPs, indicating that their abundances and phosphorylation levels both were collectively altered in gastric 
cancers. Finally, a set of the networks were associated with multiple CCs. Lysosome (Fig. 4d, left) was associated 
with both CC1 and CC3 (Fig. 3c,e). CC1 was defined by Group 1 (DEPs), while CC3 was by Group 5 (DEPs and 
DGPs). Similarly, calcium signaling network (Fig. 4d, right) was associated with both CC1 and CC3 (Fig. 3c,e) 
defined by the DPPs and/or DEPs (Groups 2 and 4). The pathways in the network models were previously reported 
in association with gastric cancers (Supplementary Table S9), supporting the validity of the network models. 
Thus, these networks demonstrated the power of complementary coverages provided by the three proteomes in 
understanding altered activities of the protein networks in gastric cancers.
Effective prioritization of key network regulators by complementary coverages. The improved 
network coverage by multi-dimensional proteomes can provide additional insights into functions of the networks. 
www.nature.com/scientificreports/
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Figure 4. Network models delineating complementary coverages of cellular protein networks provided by 
the three proteomes. (a) PPAR and ErbB signaling networks representing Complementary Coverage 1, which 
were mainly defined by the DEPs and DPPs, respectively. Colored nodes, nodes with gray boundary, and V-shaped 
nodes represent the DEPs, DPPs, and DGPs, respectively. The nodes in the network models were arranged based on 
the structures of the corresponding KEGG networks. The arrows and inhibition symbols represent the activation 
and repression information, respectively, obtained from the KEGG networks and gray edges represent PPIs 
among the nodes obtained from the six databases (Methods). Plasma membrane was denoted as the blue lines. 
Backgrounds represent functional modules in the KEGG networks. (b) PI3K-AKT signaling network representing 
Complementary Coverage 2 and 3. (c) Phosphatidylinositol signaling system network representing Complementary 
Coverage 3. (d) Cellular networks defined by two types of the complementary coverages (Complementary Coverage 
1 and 3): lysosome network defined by Groups 1 and 5 and calcium signaling network defined by Groups 2 and 4.
www.nature.com/scientificreports/
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To test this, we investigated whether the improved coverage enabled effective prioritization of key regulators in 
the networks. First, a hub-like molecule with a large number of interactors critically affects functions of the 
networks42. Thus, we examined whether the improved coverages affected identification of hub-like molecules. 
To this end, we identified 154, 232, 160, and 233 hub-like molecules for the four sets of altered molecules (DEPs, 
DEP + DPPs, DEP + DGPs, and DEP + DPP + DGPs), respectively, based on the protein-protein interactome 
data obtained from the six databases as described in Methods.
Comparison of hub-like molecules for the four sets showed that DEP + DPPs and DEP + DGPs identified 
additionally 84 and 6 hub-like molecules, respectively (Fig. 5a), compared to the DEPs, and DEP + DPP + DGPs 
identified additionally 89 hub-like molecules, indicating that the multi-dimensional proteomes enabled identi-
fication of hub-like molecules unidentifiable using single types of the proteomes. Interestingly, of the hub-like 
molecules, 148 were identified for all the four sets, suggesting their reliability as hub-like molecules. To examine 
how the extended list of hub-like molecules contributed to interpretation of cellular networks, we analyzed the 
numbers of the hub-like molecules in the four groups of signaling molecules (ligands, receptors, kinases/phos-
phatases, and TFs) and found that DPPs and DGPs provided additional hub-like molecules of kinases/phosphatases 
and receptor ligands, respectively, thereby enhancing understanding of their functions in gastric cancer-related 
networks (Fig. 5b).
Next, clustering coefficients for nodes represent how densely interactors of the nodes are connected. The nodes 
with large clustering coefficients (NLCCs) can be highly influential in functions of the networks through dense con-
nections with their interactors. Thus, we examined whether the improved coverage affected identification of NLCCs. 
We first identified 66, 57, 66, and 75 NLCCs for DEPs, DEP + DPPs, DEP + DGPs, and DEP + DPP + DGPs, 
respectively (Methods). Similarly, DEP + DPPs and DEP + DPP + DGPs identified additional 22 and 31 NLCCs, 
respectively (Fig. 5c), compared to the DEPs, which provided additional NLCCs of kinases/phosphatases and 
Figure 5. Effective identification and prioritization of key network regulators by the complementary 
multi-dimensional proteomes. (a) Relationships of hub-like molecules identified for the four sets of the altered 
proteins in gastric cancers: DEPs, DEP + DPPs, DEP + DGPs, and DEP + DPP + DGPs. Total numbers of 
hub-like molecules identified for the four sets were denoted in parenthesis. Red numbers indicate additional 
hub-like molecules identified by including DPPs or DGPs. (b) Numbers of hub-like molecules involved in the 
indicated four groups of signaling molecules. Colored stacked bar graphs showed incremental identifications of 
hub-like molecules and nodes with large clustering coefficients by the indicated multi-dimensional proteomes 
(see color legend). (c) Relationships of nodes with large clustering coefficients identified for the four sets of 
the altered proteins. (d-e) Key TFs (d) and kinases (e) identified using the DEPs and DPPs. Z scores represent 
the significance of the TFs and kinases having their downstream targets. Color bar, gradients of the Z scores. 
(f) Increased density of the networks describing interactions among the key TFs and kinases by the multi-
dimensional proteomes. *P < 0.05; ***P < 0.001.
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receptor ligands, as in the case of the hub-like molecules (Fig. 5b). Of the NLCCs, 35 were identified for all the four 
sets of altered molecules, thereby enabling effective prioritization of NLCCs in gastric cancer-related networks.
The TFs and kinases having significant numbers of altered proteins as downstream targets can be considered 
as key regulators underlying alterations in the measured proteomes. To identify these key TFs and kinases, we 
performed the enrichment analyses of TFs and kinases for the DEPs and DPPs based on the 304,217 protein-DNA 
and 5,563 kinase-substrate interaction data, respectively, obtained from the seven databases and the three databases, 
as described in Methods, and then selected the key TFs and kinases (P < 0.05) whose expression or phosphoryl-
ation levels were altered in gastric cancers. Only using the DEPs, we identified eight key TFs (RUNX1, GATA6, 
IRF4, MAZ, YBX1, SOX9, STAT1, and HNF1B), but using DEP + DPPs, we identified eight key TFs additionally 
(CEBPB/E, FOXO3, JUN, JUNB/D, PURA, and GATA5) (Fig. 5d). Similarly, using DEP + DPPs, the kinase enrich-
ment analysis identified five key kinases (ADRBK1, MTOR, GSK3A, PAK2, and MAPK1) additionally to nine key 
kinases identified from the DEPs only (Fig. 5e). The increased numbers of key kinases and TFs led to improved 
coverage of cellular networks represented by them, thereby facilitating interpretation of the key protein networks 
altered in gastric cancers (Fig. 5f).
Discussion
How much added value the multi-dimensional proteomic analyses can provide in understanding cellular networks 
is unclear, despite significant amounts of resources required for the multi-dimensional analyses. Here, we first 
proposed the SEPG method for effective multi-dimensional proteomic analyses. In the SEPG, mRP fractionation 
provided complex peptide mixtures with uniform and wide separation space, and the use of TEAB as buffer solvents 
provided compatibility with iTRAQ samples and high volatility, leading to no desalting steps during the entire 
procedure, and also low detrimental effects on separation columns. Thus, the SEPG resulted in large proteome 
coverages, alleviating the undersampling issues. Furthermore, the FASP digestion methods used in the SEPG pro-
vided a wide range of the proteome that includes nuclear, membranous, and secreted extracellular proteins. The 
larger and wider proteomes demonstrated the utility of the SEPG as an effective approach for multi-dimensional 
proteomic analyses. Importantly, the proposed SEPG, compared to previous methods, is unique in that it was 
successfully applied to human patient tissues for the multi-dimensional analyses.
In this study, we performed multi-dimensional proteomic profiling on the pairs of tumor and adjacent normal 
tissues collected from three different patients (n = 3). The reproducibility of proteomic analysis is essential to 
draw reliable conclusions on the complementary coverages of cellular networks altered in gastric cancers. For each 
patient, we generated two independent replicates from the tumor and adjacent normal tissue masses, respectively, 
and then labeled the resulting four independent peptide samples using iTRAQ (Supplementary Methods). To 
assess the reproducibility in our proteomic analysis, we performed two analyses that have been used to assess the 
reproducibility of MS-based proteomic analysis. First, we evaluated the similarity of the two replicates generated 
for adjacent normal or tumor tissue from each patient in intensities of identified peptides (Supplementary Fig. 
S4), which provides the assessment of the reproducibility in the early steps of sample preparation (lysis, protein 
isolation and digestion, and labeling). Large correlation coefficients (≥0.95) in the three types of proteomic data 
suggest high reproducibility in the early steps of sample preparation. Second, we also evaluated the similarities of 
identified peptides (ID similarity) and their intensities (Intensity similarity) in the data obtained from the three 
patients as previously reported for the three types of proteomic data (Supplementary Fig. S5), which provides 
the assessment of the reproducibility in the late steps of sample preparation (fractionation and enrichment) and 
LC-MS/MS analysis for three different patients. Overall similarity scores were found to be sufficiently high (average 
overall similarity scores = 0.77, 0.66, and 0.71 for global protein expression, phosphopeptide, and N-glycopeptide 
data), suggesting the consistency in the late steps of sample preparation and LC-MS/MS analysis for three different 
patients. Collectively, all these data suggest high quality of proteomic analyses and resulting data given the varia-
bility in the sample, both the early and late steps of sample preparation, as well as LC-MS/MS and data analyses.
In this study, we pooled the three sets of proteins (Global) and differentially expressed proteins (DEPs) iden-
tified from global protein expression data generated from three gastric cancer patients into ‘Global set’ and ‘DEP 
set’, respectively. Similarly, proteins that have phosphopeptides (Phospho), differentially phosphorylated peptides 
(DPPs), N-glycopeptides, and differentially glycosylated peptides (DGPs) identified from the three patients were 
pooled into ‘Phospho set’, ‘DPP set’, ‘N-glyco set’, and ‘DGP set’, respectively. These pooled sets were used to map 
the detected proteins into cellular networks (Global, Phospho, and N-glyco sets; Fig. 2), to analyze complementary 
coverages of cellular networks provided by the multi-dimensional data (DEP, DPP, and DGP sets; Fig. 3), and to 
reconstruct the network models for the complementary coverages (Fig. 4). However, with the pooled sets, it is not 
clear whether the results from the individual analyses mentioned above were consistent in all three patients. To 
identify patient-specific information (e.g., subtypes of gastric cancers and proteomic signatures defining the sub-
types), the multi-dimensional proteomic analysis should be performed for a large size of samples (e.g., hundreds of 
samples), as demonstrated in the TCGA genomic analyses. However, the main goal in this study is to demonstrate 
that the multi-dimensional proteomic analysis provides complementary coverages of cellular networks, rather than 
to identify the subtypes of patients. Nonetheless, it is important to draw reliable conclusions from the individual 
analyses, which hold in all three patients. To examine this aspect, we analyzed whether the multi-dimensional data 
generated from three different patients consistently contributed to the outputs from the individual analyses. To this 
end, we identified the sets individually (individual sets) from the three patients (e.g., Global sets 1–3 for patients 
1–3, respectively) and then analyzed how many of the proteins in the individual sets contributed to the analysis 
outputs obtained from the pooled sets. For example, we showed that the three proteomes increased cumulatively 
the coverage of the cellular proteome, as shown in Fig. 2b. Consistently, the increase was observed consistently in 
all the three patients (Supplementary Fig. S6a), indicating that the individual sets obtained from the three patients 
consistently contributed to the increased coverage shown in Fig. 2b. Also, the individual sets consistently con-
tributed to the following conclusions obtained from the pooled sets: 1) preferential enrichment of N-glycosylated 
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proteins in plasma membrane, ER/Golgi secretory pathways, and extracellular region (Supplementary Fig. S6b) 
and also in receptor ligands and receptors of cellular signaling networks (Supplementary Fig. S6c); 2) preferential 
enrichment of phosphorylated proteins in kinases/phosphatases of cellular signaling networks (Supplementary 
Fig. S6c); 3) complementary coverages (CC1-4) of cellular networks defined by the multi-dimensional data shown 
in Figs 3c–f (Supplementary Fig. S6d-g); and network models for the complementary coverages shown in Fig. 4 
(Supplementary Fig. S6h-k). All these data suggest that the three patients consistently contributed to the outputs 
resulted from the individual analyses, thus supporting the validity of the conclusions drawn from the pooled sets.
The integrated analyses of the three proteomes generated by the SEPG further revealed the power of 
multi-dimensional proteomic analyses in understanding of disease-related networks. Phosphoproteome captured 
predominantly signaling proteins (kinases/phosphatases and TFs) in disease-related signaling networks, while 
N-glycoproteome captured the proteins localized in plasma membrane, ER/Golgi apparatus, and extracellular 
regions (receptor ligands and receptors). Global proteome also provided protein abundances uniformly across 
the five groups of disease-related networks (Supplementary Fig. S3 and Fig. 2d). Finally, the integrated analysis 
of altered proteins under diseased conditions enabled effective identification and prioritization of key regulators 
(hub-like molecules, NLCCs, or key TFs/kinases) in disease-related networks. Therefore, our integrated analyses 
demonstrated that the three proteomes generated by the SEPG systematically improved the coverages of cellular 
networks, thereby facilitating functional interpretation of disease-related networks.
In summary, our multi-dimensional proteomic approach, including the SEPG and the integrated analyses 
of the three proteomes, provided new knowledge regarding alterations of disease-related networks in terms of 
CC1-4 of cellular networks and also key network regulators. This knowledge can be used as a comprehensive 
basis to understand functions of disease-related networks. Furthermore, our approach can be applied to other 
diseases in which multi-dimensional proteomic analyses are needed because single types of the proteomes (e.g. 
global proteomes) have failed to understand core disease-related networks and/or to identify key regulators of the 
disease-related networks.
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